Liquidia Corporation

NASDAQ:LQDA

Biotechnology

Healthcare
$56.40 +0.34%

+$0.23 today

Market cap
$5.08B
Beta
0.59
P/E (TTM)
271.8
EPS (TTM)
$0.25
52W Low $11.85High $73.22

Volume 1.22M

Average 1.50M

LQDA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Liquidia CorporationNASDAQ: LQDA

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 93.3%

Gross margin was 93.3% in Q2 FY2026, up 7.9 pp from a year earlier. On a trailing-twelve-month basis it was 92.5%, up 22.1 pp year over year. Over 3 fiscal years it widened by 9.6 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
93.3%+2.4 pp QoQ
Last fiscal yearDec 2025
91.6%+33.6 pp YoY
LTMJun 2026
92.5%+22.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+7.9 pp——
1 year+33.6 pp——
3 years+9.6 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
91.6%
Year-over-year change
+33.6pp

Gross Margin vs competitors

How LQDA compares with its peers on the latest reported figures

  • LQDA's LTM Jun 2026 gross margin of 92.5% is the 2nd highest of the 4 companies compared; the peer median is 86.1%.
  • Its year-over-year change of +22.1 pp is the highest of 4, against a peer median of +7.6 pp.
  • Over three fiscal years its change of +9.6 pp compares with a peer median of -1.3 pp.
LQDA Competitors Peer median
Gross Margin for LQDA and competitors
Company Period LTM level YoY 3-year change
VCREVicore Pharma Holding ABLTM Jun 2026100.0% +17.9 pp—
LQDALiquidia CorporationLTM Jun 202692.5% +22.1 pp+9.6 pp
UTHRUnited Therapeutics CorporationLTM Jun 202686.1% -2.8 pp-4.5 pp
INSMInsmed IncorporatedLTM Jun 202683.3% +7.6 pp+1.9 pp
AVLNAvalyn Pharma Inc. Common Stock—— ——
Peer median (excluding LQDA) 86.1%+7.6 pp-1.3 pp

Competitors are the stored peer set for LQDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.85M15.94M17.49M14M158.32M
Cost of Revenue3.02M2.86M2.89M5.88M13.24M
Gross Profit9.83M13.08M14.6M8.12M145.08M
Gross Margin76.5%82.1%83.5%58.0%91.6%
Research & Development20.52M19.44M43.24M47.84M39.28M
Selling, General & Admin23.11M32.41M44.74M81.57M157.18M
Operating Expenses43.63M51.85M87.98M129.41M196.45M
Depreciation & Amortization5.61M3.65M2.18M2.2M1.53M
EBITDA(28.21M)(35.03M)(70.05M)(115.71M)(43.22M)
EBITDA Margin-219.4%-219.8%-400.6%-826.7%-27.3%
Operating Income(33.8M)(38.77M)(73.38M)(121.29M)(51.38M)
Operating Margin-263.0%-243.3%-419.6%-866.6%-32.5%
Interest Income33K1.09M3.47M7.65M6.62M
Interest Expense762K2.34M6.27M12.49M24.17M
Other Income / Expenses(782K)(2.25M)(5.12M)(9.1M)(17.55M)
Income Before Tax(34.58M)(41.02M)(78.5M)(130.39M)(68.92M)
Pre-Tax Margin-269.0%-257.4%-448.9%-931.7%-43.5%
Income Tax Expense00000
Net Income(34.58M)(41.02M)(78.5M)(130.39M)(68.92M)
Net Margin-269.0%-257.4%-448.9%-931.7%-43.5%
EPS (Basic)(0.70)(0.67)(1.21)(1.66)(0.80)
EPS (Diluted)(0.70)(0.67)(1.21)(1.66)(0.80)
Weighted Avg Shares49.68M60.96M64.99M78.71M86.06M
Weighted Avg Shares (Diluted)49.68M60.96M64.99M78.71M86.06M

Liquidia Corporation

NASDAQ:LQDA

Intrinsic Alpha fair value

Locked

Current Price

$56.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.